{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:36:59Z","timestamp":1788799019674,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Classical MPNs including ET and PMF have a chronic course and potential for leukaemic transformation. Timely diagnosis is obligatory to ensure appropriate management and positive outcomes. The aim of this study was to determine the mutational profile, clinical characteristics and outcome of ET and PMF patients in Pakistani population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective observational study conducted between 2012 and 2017 at NIBD. Patients were diagnosed and risk stratified according to international recommendations. Response to treatment was assessed by IWG criteria.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of the total 137 patients analysed, 75 were ET and 62 were PMF. <jats:italic>JAK2<\/jats:italic> positivity was seen in 51 cases (37.2%), <jats:italic>CALR<\/jats:italic> in 41 cases (29.9%), while triple-negative in 17 (12.4%) cases. None of the patients in the present study were MPL positive. Overall survival for patients with ET and PMF was 92.5 and 86.0% respectively and leukaemia free survival was 100 and 91.6% respectively, at a median follow-up of 12\u2009months. Leukaemic transformation occurred in 6.5% of MF patients; among them, <jats:italic>JAK2<\/jats:italic> mutation was frequently found. Molecular mutations did not influence the OS in ET whereas in PMF, OS was shortest in the triple-negative PMF group as compared to the <jats:italic>JAK2<\/jats:italic> and <jats:italic>CALR<\/jats:italic> positive patient groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study shows a different spectrum of molecular mutations in ET and PMF patients in Pakistani population as compared to other Asian countries. Similarly, the risk of leukaemic transformation in ET and PMF is relatively lower in our population of patients. The factors responsible for these phenotypic and genotypic differences need to be analysed in large scale studies with longer follow-up of patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-6700-3","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T14:02:50Z","timestamp":1584021770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1593-196X","authenticated-orcid":false,"given":"Uzma","family":"Zaidi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Sufaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munazza","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3153-0672","authenticated-orcid":false,"given":"Bushra","family":"Kaleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidra","family":"Maqsood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samina Naz","family":"Mukry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rifat Zubair Ahmed","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Munzir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munira","family":"Borhany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir Sultan","family":"Shamsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"6","key":"6700_CR1","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/ajh.23690","volume":"89","author":"GJ Titmarsh","year":"2014","unstructured":"Titmarsh GJ, Duncombe AS, McMullin MF, O'rorke M, Mesa R, De Vocht F, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89(6):581\u20137.","journal-title":"Am J Hematol"},{"issue":"3","key":"6700_CR2","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3109\/10428194.2013.813500","volume":"55","author":"J Mehta","year":"2014","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma. 2014;55(3):595\u2013600.","journal-title":"Leuk Lymphoma"},{"issue":"16","key":"6700_CR3","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","volume":"124","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124(16):2507\u201313.","journal-title":"Blood"},{"issue":"6","key":"6700_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukaemia. 2010;24(6):1128\u201338.","journal-title":"Leukaemia"},{"issue":"20","key":"6700_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukaemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"issue":"25","key":"6700_CR6","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"3","key":"6700_CR7","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1096\/fj.09-145482","volume":"24","author":"LI Gold","year":"2010","unstructured":"Gold LI, Eggleton P, Sweetwyne MT, Van Duyn LB, Greives MR, Naylor S-M, et al. Calreticulin: non-endoplasmic reticulum functions in physiology and disease. FASEB J. 2010;24(3):665\u201383.","journal-title":"FASEB J"},{"issue":"6","key":"6700_CR8","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.blre.2016.06.001","volume":"30","author":"T Barbui","year":"2016","unstructured":"Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi A, Tefferi A. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30(6):453\u20139.","journal-title":"Blood Rev"},{"key":"6700_CR9","doi-asserted-by":"crossref","unstructured":"Gisslinger H, editor. Update on diagnosis and management of essential thrombocythemia. Seminars in thrombosis and hemostasis; Copyright\u00a9 2006 by Thieme medical publishers, Inc., New York. 2006.","DOI":"10.1055\/s-2006-942764"},{"issue":"2","key":"6700_CR10","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/sj.leu.2401270","volume":"13","author":"C Besses","year":"1999","unstructured":"Besses C, Cervantes F, Pereira A, Florensa L, Sole F, Hernandez-Boluda J, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukaemia. 1999;13(2):150\u20134.","journal-title":"Leukaemia"},{"issue":"11","key":"6700_CR11","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.3324\/haematol.13346","volume":"93","author":"F Passamonti","year":"2008","unstructured":"Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, et al. Prognostic factors for thrombosis, myelofibrosis, and leukaemia in essential thrombocythemia: a study of 605 patients. Haematologica. 2008;93(11):1645\u201351.","journal-title":"Haematologica"},{"issue":"5","key":"6700_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","volume":"29","author":"A Tefferi","year":"2011","unstructured":"Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573\u201382.","journal-title":"J Clin Oncol"},{"issue":"5","key":"6700_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2008.72","volume":"22","author":"F Cervantes","year":"2008","unstructured":"Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR\/ABL-negative myeloproliferative disorders. Leukaemia. 2008;22(5):905\u201314.","journal-title":"Leukaemia"},{"issue":"17","key":"6700_CR14","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","volume":"124","author":"F Cervantes","year":"2014","unstructured":"Cervantes F. How I treat myelofibrosis. Blood. 2014;124(17):2635\u201342.","journal-title":"Blood"},{"issue":"5","key":"6700_CR15","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","volume":"114","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rationale and important changes. Blood. 2009;114(5):937\u201351.","journal-title":"Blood"},{"issue":"2","key":"6700_CR16","doi-asserted-by":"publisher","first-page":"272","DOI":"10.2353\/jmoldx.2007.060133","volume":"9","author":"Q Chen","year":"2007","unstructured":"Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn. 2007;9(2):272\u20136.","journal-title":"J Mol Diagn"},{"issue":"3","key":"6700_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ajh.23135","volume":"87","author":"A Tefferi","year":"2012","unstructured":"Tefferi A. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012;87(3):284\u201393.","journal-title":"Am J Hematol"},{"issue":"9","key":"6700_CR18","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","volume":"115","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703\u20138.","journal-title":"Blood"},{"issue":"23","key":"6700_CR19","doi-asserted-by":"publisher","first-page":"4778","DOI":"10.1182\/blood-2013-01-478891","volume":"121","author":"G Barosi","year":"2013","unstructured":"Barosi G, Mesa R, Finazzi G, Harrison C, Kiladjian J-J, Lengfelder E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121(23):4778\u201381.","journal-title":"Blood"},{"issue":"8","key":"6700_CR20","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1182\/blood-2013-03-488098","volume":"122","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: international working group-Myeloproliferative neoplasms research and treatment (IWG-MRT) and European LeukaemiaNet (ELN) consensus report. Blood. 2013;122(8):1395\u20138.","journal-title":"Blood"},{"key":"6700_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1430170","volume":"2019","author":"Q Rizvi","year":"2019","unstructured":"Rizvi Q, Zaidi U, Shahid S, Ahmed S, Shamsi T. Homozygous CALR mutation in primary Myelofibrosis and its effect on disease phenotype: a case report and review of the literature. Case Rep Hematol. 2019;2019:1\u20134.","journal-title":"Case Rep Hematol"},{"key":"6700_CR22","doi-asserted-by":"publisher","unstructured":"Tefferi A, Vannucchi AM. Genetic Risk Assessment in Myeloproliferative Neoplasms. Mayo Clin Proc. 2017;92(8):1283-90. https:\/\/doi.org\/10.1016\/j.mayocp.2017.06.002.","DOI":"10.1016\/j.mayocp.2017.06.002"},{"issue":"1","key":"6700_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2016","unstructured":"Tefferi A, Lasho TL, Guglielmelli P, Finke CM, Rotunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1(1):21\u201330.","journal-title":"Blood Adv"},{"issue":"7","key":"6700_CR24","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015;372(7):601\u201312.","journal-title":"N Engl J Med"},{"issue":"9","key":"6700_CR25","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"A Vannucchi","year":"2013","unstructured":"Vannucchi A, Lasho T, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, et al. Mutations and prognosis in primary myelofibrosis. Leukaemia. 2013;27(9):1861\u20139.","journal-title":"Leukaemia"},{"issue":"4","key":"6700_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","volume":"7","author":"RL Levine","year":"2005","unstructured":"Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387\u201397.","journal-title":"Cancer Cell"},{"issue":"17","key":"6700_CR27","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo S-S, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779\u201390.","journal-title":"N Engl J Med"},{"issue":"7037","key":"6700_CR28","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/nature03546","volume":"434","author":"C James","year":"2005","unstructured":"James C, Ugo V, Le Cou\u00e9dic J-P, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144\u20138.","journal-title":"Nature"},{"issue":"9464","key":"6700_CR29","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054\u201361.","journal-title":"Lancet"},{"issue":"7","key":"6700_CR30","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3346\/jkms.2015.30.7.882","volume":"30","author":"BH Kim","year":"2015","unstructured":"Kim BH, Cho Y-U, Bae M-H, Jang S, Seo E-J, Chi H-S, et al. JAK2 V617F, MPL, and CALR mutations in Korean patients with essential thrombocythemia and primary myelofibrosis. J Korean Med Sci. 2015;30(7):882\u20138.","journal-title":"J Korean Med Sci"},{"issue":"5","key":"6700_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.leukres.2015.02.006","volume":"39","author":"N Li","year":"2015","unstructured":"Li N, Yao Q-M, Gale RP, Li J-L, Li L-D, Zhao X-S, et al. Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations. Leukaemia Res. 2015;39(5):510\u20134.","journal-title":"Leukaemia Res"},{"issue":"10","key":"6700_CR32","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood"},{"issue":"3","key":"6700_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/ajh.24978","volume":"93","author":"A Tefferi","year":"2018","unstructured":"Tefferi A, Nicolosi M, Mudireddy M, Szuber N, Finke CM, Lasho TL, et al. Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. Am J Hematol. 2018;93(3):348\u201355.","journal-title":"Am J Hematol"},{"issue":"10","key":"6700_CR34","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","volume":"108","author":"AD Pardanani","year":"2006","unstructured":"Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472\u20136.","journal-title":"Blood."},{"issue":"7","key":"6700_CR35","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho T, Finke C, Knudson R, Ketterling R, Hanson C, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukaemia. 2014;28(7):1472\u20137.","journal-title":"Leukaemia"},{"issue":"7","key":"6700_CR36","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Mart\u00ednez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(7):1062\u20139.","journal-title":"Blood"},{"issue":"5","key":"6700_CR37","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","volume":"82","author":"K Hussein","year":"2009","unstructured":"Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009;82(5):329\u201338.","journal-title":"Eur J Haematol"},{"issue":"3","key":"6700_CR38","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","volume":"113","author":"A Tefferi","year":"2001","unstructured":"Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001;113(3):763\u201371.","journal-title":"Br J Haematol"},{"issue":"9","key":"6700_CR39","doi-asserted-by":"publisher","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","volume":"107","author":"F Passamonti","year":"2006","unstructured":"Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676\u201382.","journal-title":"Blood"},{"issue":"2","key":"6700_CR40","first-page":"169","volume":"91","author":"E Arellano-Rodrigo","year":"2006","unstructured":"Arellano-Rodrigo E, Alvarez-Larr\u00e1n A, Reverter JC, Villamor N, Colomer D, Cervantes F. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91(2):169\u201375.","journal-title":"Haematologica"},{"key":"6700_CR41","doi-asserted-by":"crossref","unstructured":"Kundranda MN, Maiti B, Iqbal N, Muslimani AA, Chaudhry A, Spiro TM, et al. The association of leukocytosis, thrombocytosis and JAK2V617F mutation with thrombotic events in myeloproliferative disorders (MPD\u2019s). Blood. 2008;112(11):2803.","DOI":"10.1182\/blood.V112.11.2803.2803"},{"issue":"8","key":"6700_CR42","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1038\/leu.2008.177","volume":"22","author":"G Finazzi","year":"2008","unstructured":"Finazzi G, Barbui T. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia. Leukaemia. 2008;22(8):1494\u2013502.","journal-title":"Leukaemia"},{"issue":"10","key":"6700_CR43","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","volume":"123","author":"G Rotunno","year":"2014","unstructured":"Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552\u20135.","journal-title":"Blood"},{"issue":"4","key":"6700_CR44","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1182\/blood-2009-02-206797","volume":"114","author":"T Barbui","year":"2009","unstructured":"Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009;114(4):759\u201363.","journal-title":"Blood"},{"issue":"8","key":"6700_CR45","doi-asserted-by":"publisher","first-page":"E121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89(8):E121\u2013E4.","journal-title":"Am J Hematol"},{"issue":"7","key":"6700_CR46","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.3324\/haematol.2014.107482","volume":"99","author":"H Andrikovics","year":"2014","unstructured":"Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M, et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations. Haematologica. 2014;99(7):1184\u201390.","journal-title":"Haematologica"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6700-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6700-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T00:29:19Z","timestamp":1615508959000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6700-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6700"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6700-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"14 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the ethics committee of NIBD and BMT (NIBD\/RD-135\/15\u20132013). Informed written consent was obtained from all patients before capturing the data in the electronic database system.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"205"}}